-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Affected by the development of the pharmaceutical industry, market environment and corporate layout, many companies have announced decisions to transfer or acquire equity
.
For example, on January 17, 2022, Zhejiang Xianju Pharmaceutical Co.
, Ltd.
issued an announcement on the proposed transfer of 61.
2% equity of the holding subsidiary Haisheng Pharmaceutical
.
According to the announcement issued by Xianju Pharmaceutical, Taizhou Haisheng Pharmaceutical Co.
, Ltd.
is a holding subsidiary of the company with a registered capital of 5 million yuan.
The company holds 61.
2% of the equity of Haisheng Pharmaceutical
.
However, Haisheng Pharmaceutical's main business is vitamin D3 API manufacturing, food additive manufacturing, etc.
, which has no synergistic effect with the company's steroid hormone industry chain
.
The subsequent production transformation and new product expansion of Haisheng Pharmaceutical will require continuous investment, which is uncertain
.
In view of the above situation, according to the development plan, Xianju Pharmaceutical focuses on the main business of steroid hormones, and plans to publicly list and transfer it through public listing on the property exchange in accordance with the state-owned asset disposal procedures, with an equity value not lower than the target evaluation value.
The company holds a 61.
2% stake in Haisheng Pharmaceutical
.
It is worth noting that on January 6, 2022, Xianju Pharmaceutical also issued a progress announcement on the public listing and transfer of part of the equity of the participating company
.
According to the announcement, the 15% equity of Zijing Bio held by Xianju Pharmaceutical was officially listed on Zhejiang Equity Exchange Co.
, Ltd.
on November 25, 2021.
After the expiration of the listing announcement on December 22, 2021, Zhejiang Equity Exchange According to the provisions of the "Instructions for Dynamic Quotation Transactions" and the results of dynamic quotations on the Internet, it was confirmed that Quanxinjili (Ningbo) Biotechnology Partnership (Limited Partnership) bid to become the transferee of 15% equity of Zijing Biotechnology at a price of RMB 6.
45 million.
.
After the completion of the equity transfer, Xianju Pharmaceutical's shareholding ratio in Zijing Bio will be reduced from the current 49% to 34%, without involving the change of the scope of the company's consolidated statements
.
It is understood that in addition to Xianju Pharmaceutical, on January 11, 2022, Zhejiang Asia-Pacific Pharmaceutical Co.
, Ltd.
also issued a reminder announcement on the transfer of company shares and changes in equity by shareholder agreement
.
The content of the announcement shows that on January 11, 2022, the company received the agreement transfer notice from Bank of Ningbo and Fubon Group.
Fubon Group and Bank of Ningbo signed the "Share Transfer Agreement".
The 39,000,000 shares of Asia Pacific Pharmaceutical held by Bank of Ningbo account for 7.
27% of the total share capital of Asia Pacific Pharmaceutical
.
The transfer price of the subject shares is determined to be RMB 5.
21 per share, with a total transfer price of RMB 203,190,000.
00
.
On January 7, 2022, Hainan Shuangcheng Pharmaceutical Co.
, Ltd.
issued an announcement saying that it agreed to the company's holding subsidiary Ningbo Shuangcheng Pharmaceutical Co.
, Ltd.
to plan to own the medicine related to memantine hydrochloride tablets (5mg, 10mg) for RMB 6 million.
The rights to specific intellectual property rights and production technologies in the designated area are granted to Baishan Pharmaceutical (Huzhou) Co.
,
Ltd.
On January 5, 2022, Tonghua Dongbao announced that the company intends to transfer 20.
35 million unrestricted tradable shares of Tebao Bio, accounting for 5.
0025% of the current total share capital of Tebao Bio.
The transfer price is 22.
608 yuan per share.
The total price is $460,072,800
.
The counterparty of the transaction is Qingdao Dingxing Qiguang Medical Industry Investment Fund Partnership (Limited Partnership)
.
It is understood that back to the end of 2021, a large number of companies have also issued announcements on the sale of equity, assets,
etc.
For example, Guangdong Tai'antang Pharmaceutical Co.
, Ltd.
announced that it transferred 100% of its wholly-owned Shantou Tai'an Investment Development Co.
, Ltd.
to Shantou Real Estate Hexin Co.
, Ltd.
; Guangzhou Xiangxue Pharmaceutical Co.
, Ltd.
issued The announcement stated that the 100% equity of the subsidiary Guangdong Jiuji Daily Health Care Products Co.
, Ltd.
was transferred to Huayao Business for RMB 33 million through equity transfer
.
.
For example, on January 17, 2022, Zhejiang Xianju Pharmaceutical Co.
, Ltd.
issued an announcement on the proposed transfer of 61.
2% equity of the holding subsidiary Haisheng Pharmaceutical
.
According to the announcement issued by Xianju Pharmaceutical, Taizhou Haisheng Pharmaceutical Co.
, Ltd.
is a holding subsidiary of the company with a registered capital of 5 million yuan.
The company holds 61.
2% of the equity of Haisheng Pharmaceutical
.
However, Haisheng Pharmaceutical's main business is vitamin D3 API manufacturing, food additive manufacturing, etc.
, which has no synergistic effect with the company's steroid hormone industry chain
.
The subsequent production transformation and new product expansion of Haisheng Pharmaceutical will require continuous investment, which is uncertain
.
In view of the above situation, according to the development plan, Xianju Pharmaceutical focuses on the main business of steroid hormones, and plans to publicly list and transfer it through public listing on the property exchange in accordance with the state-owned asset disposal procedures, with an equity value not lower than the target evaluation value.
The company holds a 61.
2% stake in Haisheng Pharmaceutical
.
It is worth noting that on January 6, 2022, Xianju Pharmaceutical also issued a progress announcement on the public listing and transfer of part of the equity of the participating company
.
According to the announcement, the 15% equity of Zijing Bio held by Xianju Pharmaceutical was officially listed on Zhejiang Equity Exchange Co.
, Ltd.
on November 25, 2021.
After the expiration of the listing announcement on December 22, 2021, Zhejiang Equity Exchange According to the provisions of the "Instructions for Dynamic Quotation Transactions" and the results of dynamic quotations on the Internet, it was confirmed that Quanxinjili (Ningbo) Biotechnology Partnership (Limited Partnership) bid to become the transferee of 15% equity of Zijing Biotechnology at a price of RMB 6.
45 million.
.
After the completion of the equity transfer, Xianju Pharmaceutical's shareholding ratio in Zijing Bio will be reduced from the current 49% to 34%, without involving the change of the scope of the company's consolidated statements
.
It is understood that in addition to Xianju Pharmaceutical, on January 11, 2022, Zhejiang Asia-Pacific Pharmaceutical Co.
, Ltd.
also issued a reminder announcement on the transfer of company shares and changes in equity by shareholder agreement
.
The content of the announcement shows that on January 11, 2022, the company received the agreement transfer notice from Bank of Ningbo and Fubon Group.
Fubon Group and Bank of Ningbo signed the "Share Transfer Agreement".
The 39,000,000 shares of Asia Pacific Pharmaceutical held by Bank of Ningbo account for 7.
27% of the total share capital of Asia Pacific Pharmaceutical
.
The transfer price of the subject shares is determined to be RMB 5.
21 per share, with a total transfer price of RMB 203,190,000.
00
.
On January 7, 2022, Hainan Shuangcheng Pharmaceutical Co.
, Ltd.
issued an announcement saying that it agreed to the company's holding subsidiary Ningbo Shuangcheng Pharmaceutical Co.
, Ltd.
to plan to own the medicine related to memantine hydrochloride tablets (5mg, 10mg) for RMB 6 million.
The rights to specific intellectual property rights and production technologies in the designated area are granted to Baishan Pharmaceutical (Huzhou) Co.
,
Ltd.
On January 5, 2022, Tonghua Dongbao announced that the company intends to transfer 20.
35 million unrestricted tradable shares of Tebao Bio, accounting for 5.
0025% of the current total share capital of Tebao Bio.
The transfer price is 22.
608 yuan per share.
The total price is $460,072,800
.
The counterparty of the transaction is Qingdao Dingxing Qiguang Medical Industry Investment Fund Partnership (Limited Partnership)
.
It is understood that back to the end of 2021, a large number of companies have also issued announcements on the sale of equity, assets,
etc.
For example, Guangdong Tai'antang Pharmaceutical Co.
, Ltd.
announced that it transferred 100% of its wholly-owned Shantou Tai'an Investment Development Co.
, Ltd.
to Shantou Real Estate Hexin Co.
, Ltd.
; Guangzhou Xiangxue Pharmaceutical Co.
, Ltd.
issued The announcement stated that the 100% equity of the subsidiary Guangdong Jiuji Daily Health Care Products Co.
, Ltd.
was transferred to Huayao Business for RMB 33 million through equity transfer
.
